Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aprea Therapeutics, Inc. (APRE)
USD0.70
-0.03 (-4.20%)
US NASDAQ Healthcare Biotechnology
Address
535 Boylston St. 2116
Boston, MA, US
Boston, MA, US
CEO
Oren Gilad
Website
atrinpharma.com
IPO
2019-10-03
CIK 1781983 ISIN US03836J2015
Description
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.70
-0.03 (-4.20%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
210.1K
Beta
1.56
Float Shares
4.85M
Free Float %
74.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.22% | -5.38% | +3.90% | +44.40% | -26.05% | +3.17% | -41.33% | -75.96% | -98.91% | -99.79% | -99.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
0.70
DCF (Unlevered)
2.13
+205.9%
DCF (Levered)
2.23
+220.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-9.10
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.9% Q1'26: +66.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+18.7% Q1'26: +145.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 249.7K (-100.0%)
|
583.2K
est: 1.28M (-54.3%)
|
1.50M
est: 1.34M (+12.2%)
|
—
est: 293.7K (-100.0%)
|
150.0K
150.0K – 150.0K
-48.9% YoY
|
1.61M
1.61M – 1.61M
+971.3% YoY
|
3.41M
3.41M – 3.41M
+112.2% YoY
|
65.72M
65.72M – 65.72M
+1,826.9% YoY
|
145.23M
145.23M – 145.23M
+121.0% YoY
|
| EBITDA |
-37.37M
est: 49.9K (-74,929.6%)
|
-14.28M
est: -255.1K (-5,496.9%)
|
-14.30M
est: -267.7K (-5,240.1%)
|
-13.21M
est: -58.7K (-22,395.2%)
|
-30.0K
-30.0K – -30.0K
+48.9% YoY
|
-321.4K
-321.4K – -321.4K
-971.4% YoY
|
-682.1K
-682.1K – -682.1K
-112.2% YoY
|
-13.14M
-13.14M – -13.14M
-1,826.9% YoY
|
-29.05M
-29.05M – -29.05M
-121.0% YoY
|
| EBIT |
-37.37M
est: 49.9K (-74,938.4%)
|
-14.29M
est: -255.1K (-5,499.6%)
|
-14.32M
est: -267.7K (-5,248.5%)
|
-13.23M
est: -58.7K (-22,432.2%)
|
-30.0K
-30.0K – -30.0K
+48.9% YoY
|
-321.4K
-321.4K – -321.4K
-971.4% YoY
|
-682.1K
-682.1K – -682.1K
-112.2% YoY
|
-13.14M
-13.14M – -13.14M
-1,826.9% YoY
|
-29.05M
-29.05M – -29.05M
-121.0% YoY
|
| Net Income |
-112.66M
est: -400.57M (+71.9%)
|
-14.29M
est: -19.20M (+25.6%)
|
-12.96M
est: -16.38M (+20.9%)
|
-12.60M
est: -13.01M (+3.2%)
|
-4.47M
-5.00M – -3.95M
+65.6% YoY
|
-3.96M
-5.52M – -2.40M
+11.5% YoY
|
-5.37M
-7.32M – -3.42M
-35.7% YoY
|
882.7K
882.7K – 882.7K
+116.4% YoY
|
6.64M
6.64M – 6.64M
+651.9% YoY
|
| SGA |
20.97M
est: 1.09M (+1,831.9%)
|
8.42M
est: 11.07M (-24.0%)
|
6.46M
est: 11.62M (-44.4%)
|
6.48M
est: 2.55M (+154.1%)
|
1.30M
1.30M – 1.30M
-48.9% YoY
|
13.95M
13.95M – 13.95M
+971.3% YoY
|
29.60M
29.60M – 29.60M
+112.2% YoY
|
570.44M
570.44M – 570.44M
+1,826.9% YoY
|
1.26B
1.26B – 1.26B
+121.0% YoY
|
| EPS |
-1,359.79
est: -72.70 (-1,770.4%)
|
-3.95
est: -2.94 (-34.5%)
|
-2.35
est: -2.51 (+6.4%)
|
-1.93
est: -1.99 (+3.0%)
|
-0.70
-0.76 – -0.60
+64.8% YoY
|
-0.65
-0.84 – -0.37
+7.9% YoY
|
-0.73
-1.12 – -0.52
-13.2% YoY
|
0.14
0.14 – 0.14
+118.5% YoY
|
1.02
1.02 – 1.02
+651.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.89M
OE per share TTM
-1.71
Owner's Yield
-99.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
57.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
11
Total invested
1.32M
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HealthCap VII GP S.A. | 2.37M | 11.20% | — | 2.37M | — | 2.37M | OO | — | 2021-10-15 | ↗ |
| 2 | HealthCap VII, L.P. | 2.37M | 11.20% | — | 2.37M | — | 2.37M | PN | — | 2021-10-15 | ↗ |
| 3 | KCIF Co-Investment Fund KB | 1.78M | 8.40% | — | 1.78M | — | 1.78M | OO | Sweden | 2021-02-16 | ↗ |
| 4 | KDev Investments AB | 1.78M | 8.40% | — | 1.78M | — | 1.78M | OO | Sweden | 2021-02-16 | ↗ |
| 5 | Karolinska Development AB | 1.78M | 8.40% | — | 1.78M | — | 1.78M | OO | Sweden | 2021-02-16 | ↗ |
| 6 | 5AM Partners IV, LLC | 619.2K | 2.90% | — | 619.2K | — | 10.00 | OO | Delaware | 2021-02-16 | ↗ |
| 7 | Andrew J. Schwab | 619.2K | 2.90% | — | 619.2K | — | 10.00 | IN | United States | 2021-02-16 | ↗ |
| 8 | Dr. John D. Diekman | 619.2K | 2.90% | — | 619.2K | — | 10.00 | IN | United States | 2021-02-16 | ↗ |
| 9 | Dr. Scott M. Rocklage | 619.2K | 2.90% | — | 619.2K | — | 10.00 | IN | United States | 2021-02-16 | ↗ |
| 10 | 5AM Ventures IV, L.P. | 594.4K | 2.80% | — | 594.4K | — | 10.00 | PN | Delaware | 2021-02-16 | ↗ |
| 11 | Jon M. Plexico | 365.4K | 11.00% | — | 365.4K | — | 365.4K | HC, IN | U.S.A. | 2024-10-10 | ↗ |
| 12 | Stonepine Capital Management, LLC | 365.4K | 11.00% | — | 365.4K | — | 365.4K | IA, OO | Delaware | 2024-10-10 | ↗ |
| 13 | Stonepine Capital, L.P. | 365.4K | 11.00% | — | 365.4K | — | 365.4K | PN | Delaware | 2024-10-10 | ↗ |
| 14 | Stonepine GP, LLC | 365.4K | 11.00% | — | 365.4K | — | 365.4K | OO | Delaware | 2024-10-10 | ↗ |
| 15 | (. | 345.0K | 9.20% | — | — | 345.0K | — | IN | United States | 2023-03-03 | ↗ |
| 16 | 27-4413262 | 345.0K | 9.20% | — | — | 345.0K | — | OO | Maryland | 2023-03-03 | ↗ |
| 17 | Sio Capital Management, LLC 20-4586565 | 280.0K | 7.49% | — | 280.0K | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 18 | Morgan Stanley | 185.0K | 0.90% | — | 184.0K | — | 185.0K | HC, CO | Delaware. | 2021-10-12 | ↗ |
| 19 | Morgan Stanley Capital Services LLC | 184.0K | 0.90% | — | 184.0K | — | 184.0K | CO | Delaware. | 2021-10-12 | ↗ |
| 20 | Jérôme G. Pfund | 163.7K | 0.77% | 163.7K | — | 163.7K | — | IN | Swiss | 2021-02-12 | ↗ |
| 21 | Michael L. Sjöström | 163.7K | 0.77% | 163.7K | — | 163.7K | — | IN | Swiss | 2021-02-12 | ↗ |
| 22 | Opportunities Fund III, L.P | 163.7K | 0.77% | 163.7K | — | 163.7K | — | PN | Sectoral GP III, L.P.: Canada | 2021-02-12 | ↗ |
| 23 | Sectoral Asset Management Inc. | 163.7K | 0.77% | 163.7K | — | 163.7K | — | IA | Canada | 2021-02-12 | ↗ |
| 24 | 5AM Opportunities I (GP), LLC | 138.5K | 0.70% | — | 138.5K | — | 10.00 | OO | Delaware | 2020-11-19 | ↗ |
| 25 | 13G | 36.8K | 0.20% | 36.8K | — | 36.8K | — | PN | — | 2021-02-16 | ↗ |
| 26 | 5AM Co-Investors IV, L.P. | 24.8K | 0.10% | — | 24.8K | — | 10.00 | PN | Delaware | 2021-02-16 | ↗ |
| 27 | 5AM Opportunities I, L.P. | — | 0.00% | — | — | — | 10.00 | PN | Delaware | 2021-02-16 | ↗ |
| 28 | EIN #00-0000000 | — | 0.00% | — | — | — | — | IA, HC | Jersey Channel Islands | 2021-02-11 | ↗ |
| 29 | GP-GP | — | 0.00% | — | — | — | — | CO | — | 2022-02-11 | ↗ |
| 30 | Jeremy C. Green | — | 0.00% | — | — | — | — | HC, IN | United Kingdom | 2022-02-14 | ↗ |
| 31 | Redmile Group, LLC | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 32 | Versant Affiliates Fund V, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-11 | ↗ |
| 33 | Versant Ophthalmic Affiliates Fund I, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-11 | ↗ |
| 34 | Versant Venture Capital V (Canada) LP | — | 0.00% | — | — | — | — | PN | — | 2022-02-11 | ↗ |
| 35 | Versant Venture Capital V, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-11 | ↗ |
| 36 | Versant Ventures V (Canada), L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-11 | ↗ |
| 37 | Versant Ventures V, LLC | — | 0.00% | — | — | — | — | OO | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
11
-11 vs prev Q
New positions
2
Closed positions
13
Increased
5
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | AIGH CAPITAL MANAGEMENT LLC | 370.5K -168.8K (-31.3%) | 316.1K -479.4K (-60.3%) | 5.81% -3.051 pp | 0.08% -0.148 pp | USD5.10 -83.3% | 12 qtrs — |
| 2 | MURCHINSON LTD. | 340.1K +340.1K (+100.0%) | 290.1K +290.1K (+100.0%) | 5.34% +5.337 pp | 0.05% +0.047 pp | USD0.85 +0.0% | 1 qtrs NEW |
| 3 | SPHERA FUNDS MANAGEMENT LTD. | 270.0K +— (+0.0%) | 230.3K -167.9K (-42.2%) | 4.24% -0.202 pp | 0.04% -0.040 pp | USD6.35 -86.6% | 8 qtrs — |
| 4 | NANTAHALA CAPITAL MANAGEMENT, LLC | 205.8K +— (+0.0%) | 175.5K -128.0K (-42.2%) | 3.23% -0.154 pp | 0.01% -0.005 pp | USD6.35 -86.6% | 8 qtrs — |
| 5 | DRW SECURITIES, LLC | 120.7K +120.7K (+100.0%) | 102.9K +102.9K (+100.0%) | 1.89% +1.893 pp | 0.00% +0.003 pp | USD0.85 +0.0% | 1 qtrs NEW |
| 6 | MORGAN STANLEY | 77.0K +11.2K (+17.1%) | 65.7K -31.4K (-32.3%) | 1.21% +0.127 pp | 0.00% +0.000 pp | USD2.81 -69.8% | 12 qtrs — |
| 7 | VANGUARD GROUP INC | 58.1K -100.2K (-63.3%) | 49.5K -183.9K (-78.8%) | 0.91% -1.690 pp | 0.00% +0.000 pp | USD4.76 -82.1% | 12 qtrs — |
| 8 | CITADEL ADVISORS LLC | 51.0K +51.0K (+100.0%) | 43.5K +43.5K (+100.0%) | 0.80% +0.801 pp | 0.00% +0.000 pp | USD0.85 +0.0% | 1 qtrs NEW |
| 9 | JANE STREET GROUP, LLC | 46.6K +46.6K (+100.0%) | 39.8K +39.8K (+100.0%) | 0.73% +0.732 pp | 0.00% +0.000 pp | USD0.85 +0.0% | 1 qtrs NEW |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 41.0K -3.7K (-8.2%) | 34.9K -30.9K (-46.9%) | 0.64% -0.091 pp | 0.00% +0.000 pp | USD3.55 -76.1% | 11 qtrs — |
| 11 | BNP PARIBAS ARBITRAGE, SNC | 27.3K +10.2K (+59.5%) | 23.3K -2.0K (-7.7%) | 0.43% +0.147 pp | 0.00% +0.000 pp | USD2.14 -60.3% | 5 qtrs — |
| 12 | LPL FINANCIAL LLC | 26.1K +10.0K (+62.3%) | 22.2K -1.5K (-6.1%) | 0.41% +0.145 pp | 0.00% +0.000 pp | USD2.30 -63.0% | 5 qtrs — |
| 13 | XTX TOPCO LTD | 24.3K +24.3K (+100.0%) | 20.7K +20.7K (+100.0%) | 0.38% +0.381 pp | 0.00% +0.001 pp | USD0.85 +0.0% | 1 qtrs NEW |
| 14 | HIGHTOWER ADVISORS, LLC | 13.9K +— (+0.0%) | 11.8K -8.6K (-42.2%) | 0.22% -0.010 pp | 0.00% +0.000 pp | USD6.35 -86.6% | 8 qtrs — |
| 15 | BLACKROCK, INC. | 8.5K +— (+0.0%) | 7.3K -5.3K (-42.2%) | 0.13% -0.006 pp | 0.00% +0.000 pp | USD2.75 -69.1% | 6 qtrs — |
| 16 | TOWER RESEARCH CAPITAL LLC (TRC) | 7.8K +7.3K (+1,278.0%) | 6.7K +5.8K (+696.7%) | 0.12% +0.114 pp | 0.00% +0.000 pp | USD1.01 -15.8% | 12 qtrs — |
| 17 | BANK OF AMERICA CORP /DE/ | 3.3K -1.6K (-32.1%) | 2.8K -4.4K (-60.8%) | 0.05% -0.028 pp | 0.00% +0.000 pp | USD4.07 -79.1% | 12 qtrs — |
| 18 | UBS GROUP AG | 2.5K +2.5K (+81,933.3%) | 2.1K +2.1K (+52,400.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD0.85 +0.0% | 12 qtrs — |
| 19 | GROUP ONE TRADING, L.P. | 577.00 +— (+0.0%) | 492.00 -359.0 (-42.2%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD4.44 -80.9% | 12 qtrs — |
| 20 | ADVISOR GROUP HOLDINGS, INC. | 300.00 -100.0 (-25.0%) | 255.00 -354.0 (-58.1%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD2.34 -63.7% | 12 qtrs — |
| 21 | WEALTHCOLLAB, LLC | 158.00 +— (+0.0%) | 135.00 -99.0 (-42.3%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD4.70 -81.9% | 9 qtrs — |
| 22 | SBI SECURITIES CO., LTD. | 15.00 -27.0 (-64.3%) | 13.00 -49.0 (-79.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.13 -72.8% | 5 qtrs — |
| 23 | MB, LEVIS & ASSOCIATES, LLC | — -806.0 (-100.0%) | — -1.2K (-100.0%) | 0.00% -0.013 pp | 0.00% -0.001 pp | USD— | 11 qtrs SOLD |
| 24 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | — -10.5K (-100.0%) | — -15.5K (-100.0%) | 0.00% -0.173 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 25 | HRT FINANCIAL LP | — -12.3K (-100.0%) | — -18.0K (-100.0%) | 0.00% -0.202 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 26 | DAFNA CAPITAL MANAGEMENT LLC | — -137.2K (-100.0%) | — -202.3K (-100.0%) | 0.00% -2.255 pp | 0.00% -0.050 pp | USD— | 8 qtrs SOLD |
| 27 | CITIGROUP INC | — -5.0 (-100.0%) | — -7.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 28 | SIO CAPITAL MANAGEMENT, LLC | — -112.2K (-100.0%) | — -165.5K (-100.0%) | 0.00% -1.845 pp | 0.00% -0.042 pp | USD— | 12 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 17.1K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
12
Sells
0
Shares acquired
528.7K
Shares disposed
—
Cash buys
8.00
Cash sales
—
Net activity
+528,736
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Peters Richard | Director | P-Purchase | A | Pre-Funded Warrant | 123,915 | 0.00 | 123.92 | 123,915 | D | ↗ |
| 2026-03-31 | Hamill John P. | Officer | P-Purchase | A | Pre-Funded Warrant | 30,978 | 0.00 | 30.98 | 30,978 | D | ↗ |
| 2026-03-12 | Hamill John P. | Officer | A-Award | A | Common Stock | 10,095 | 0.00 | — | 43,528 | D | ↗ |
| 2026-03-12 | Gilad Oren | Director / Officer | A-Award | A | Common Stock | 20,175 | 0.00 | — | 393,895 | D | ↗ |
| 2026-01-30 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 5,700 | 0.89 | 5.1K | 33,433 | D | ↗ |
| 2026-01-30 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 28,100 | 0.89 | 25.0K | 373,720 | D | ↗ |
| 2025-12-10 | Hamill John P. | Officer | P-Purchase | A | Common Warrant | 5,000 | 1.04 | 5.2K | 5,000 | D | ↗ |
| 2025-12-10 | Gilad Oren | Director / Officer | P-Purchase | A | Pre-Funded Warrant | 21,459 | 0.00 | 2.15 | 21,459 | D | ↗ |
| 2025-12-10 | Duey Marc | Director | P-Purchase | A | Common Stock | 21,459 | 1.17 | 25.0K | 256,155 | D | ↗ |
| 2025-06-05 | Seizinger Bernd R. | Director | A-Award | A | Common Stock | 1,045 | 0.00 | — | 45,775 | D | ↗ |
| 2025-06-05 | Peters Richard | Director | A-Award | A | Common Stock | 1,045 | 0.00 | — | 3,119 | D | ↗ |
| 2025-06-05 | Pamukcu Rifat | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 1.81 | 7.6K | 4,185 | D | ↗ |
| 2025-06-05 | HENNEMAN JOHN B III | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 1.81 | 7.6K | 4,185 | D | ↗ |
| 2025-06-05 | Gruia Gabriela | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 1.81 | 7.6K | 4,185 | D | ↗ |
| 2025-06-05 | Grissinger Michael | Director | A-Award | A | Common Stock | 1,045 | 0.00 | — | 2,889 | D | ↗ |
| 2025-06-05 | Duey Marc | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 1.81 | 7.6K | 4,185 | D | ↗ |
| 2025-06-05 | BIZZARI JEAN-PIERRE | Director | A-Award | A | Common Stock | 1,045 | 0.00 | — | 1,045 | D | ↗ |
| 2025-04-03 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 2,497 | 1.80 | 4.5K | 345,620 | D | ↗ |
| 2025-03-27 | Hamill John P. | Officer | A-Award | A | Common Stock | 3,365 | 0.00 | — | 22,733 | D | ↗ |
| 2025-03-27 | Gilad Oren | Director / Officer | A-Award | A | Common Stock | 6,725 | 0.00 | — | 340,120 | D | ↗ |
| 2024-10-23 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 500 | 3.92 | 2.0K | 333,395 | D | ↗ |
| 2024-10-18 | Duey Marc | Director | S-Sale | D | Common Stock | 6,462 | 4.58 | 29.6K | 233,651 | D | ↗ |
| 2024-10-16 | Duey Marc | Director | P-Purchase | A | Common Stock | 30,000 | 4.39 | 131.7K | 240,113 | D | ↗ |
| 2024-10-15 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 250 | 2.90 | 725.00 | 332,895 | D | ↗ |
| 2024-10-14 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 2.59 | 2.6K | 332,645 | D | ↗ |
| 2024-10-14 | Duey Marc | Director | P-Purchase | A | Common Stock | 190 | 2.58 | 490.20 | 210,113 | D | ↗ |
| 2024-10-11 | Seizinger Bernd R. | Director | P-Purchase | A | Common Stock | 10,000 | 2.68 | 26.8K | 44,730 | D | ↗ |
| 2024-10-11 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 50 | 2.46 | 123.19 | 19,368 | D | ↗ |
| 2024-10-10 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 450 | 2.61 | 1.2K | 19,318 | D | ↗ |
| 2024-10-10 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 150 | 2.54 | 381.00 | 331,645 | D | ↗ |
| 2024-06-20 | Seizinger Bernd R. | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 4.07 | 17.0K | 4,185 | — | ↗ |
| 2024-06-20 | Peters Richard | Director | A-Award | A | Common Stock | 1,045 | 0.00 | — | 2,074 | — | ↗ |
| 2024-06-20 | Pamukcu Rifat | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 4.07 | 17.0K | 4,185 | — | ↗ |
| 2024-06-20 | HENNEMAN JOHN B III | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 4.07 | 17.0K | 4,185 | — | ↗ |
| 2024-06-20 | Grissinger Michael | Director | A-Award | A | Common Stock | 1,045 | 0.00 | — | 1,844 | — | ↗ |
| 2024-06-20 | Duey Marc | Director | A-Award | A | Stock Options (Right to Buy) | 4,185 | 4.07 | 17.0K | 4,185 | — | ↗ |
| 2024-05-01 | Mirza Nadeem Q. | Officer | A-Award | A | Stock Options (Right to Purchase) | 26,920 | 5.25 | 141.3K | 26,920 | — | ↗ |
| 2024-03-28 | Hamill John P. | Officer | A-Award | A | Common Stock | 3,365 | 0.00 | — | 18,868 | — | ↗ |
| 2024-03-28 | Gilad Oren | Director / Officer | A-Award | A | Common Stock | 6,725 | 0.00 | — | 331,495 | — | ↗ |
| 2024-03-13 | Seizinger Bernd R. | Director | P-Purchase | A | Tranche B Warrant | 3,430 | 0.00 | — | 3,430 | — | ↗ |
| 2024-03-13 | Hamill John P. | Officer | P-Purchase | A | Tranche A Warrant | 505 | 0.00 | — | 505 | — | ↗ |
| 2024-03-13 | HENNEMAN JOHN B III | Director | P-Purchase | A | Tranche B Warrant | 3,430 | 0.00 | — | 3,430 | — | ↗ |
| 2024-03-13 | Gilad Oren | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 7.29 | 14.6K | 324,770 | — | ↗ |
| 2023-08-23 | Seizinger Bernd R. | Director | A-Award | A | Stock Options (Right to Buy) | 2,000 | 3.65 | 7.3K | 2,000 | — | ↗ |
| 2023-08-23 | Peters Richard | Director | A-Award | A | Common Stock | 500 | 0.00 | — | 1,029 | — | ↗ |
| 2023-08-23 | Pamukcu Rifat | Director | A-Award | A | Stock Options (Right to Buy) | 2,000 | 3.65 | 7.3K | 2,000 | — | ↗ |
| 2023-08-23 | HENNEMAN JOHN B III | Director | A-Award | A | Common Stock | 500 | 0.00 | — | 1,279 | — | ↗ |
| 2023-08-23 | Grissinger Michael | Director | A-Award | A | Common Stock | 500 | 0.00 | — | 799 | — | ↗ |
| 2023-08-23 | Duey Marc | Director | A-Award | A | Stock Options (Right to Buy) | 2,000 | 3.65 | 7.3K | 2,000 | — | ↗ |
| 2023-08-23 | BIZZARI JEAN-PIERRE | Director | A-Award | A | Stock Options (Right to Buy) | 12,500 | 3.65 | 45.6K | 12,500 | — | ↗ |
| 2023-06-07 | Seizinger Bernd R. | Director | P-Purchase | A | Common Stock | 6,029 | 3.68 | 22.2K | 26,325 | — | ↗ |
| 2023-06-06 | Seizinger Bernd R. | Director | P-Purchase | A | Common Stock | 4,068 | 3.63 | 14.8K | 20,296 | — | ↗ |
| 2023-05-05 | Gruia Gabriela | Director | A-Award | A | Stock Options (Right to Buy) | 12,500 | 3.90 | 48.7K | 12,500 | — | ↗ |
| 2023-03-09 | Gilad Oren | Director / Officer | A-Award | A | Common Stock | 4,000 | 0.00 | — | 322,770 | — | ↗ |
| 2023-02-27 | Hamill John P. | Officer | A-Award | A | Common Stock | 1,000 | 5.25 | 5.3K | 14,493 | — | ↗ |
| 2023-01-30 | Hamill John P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 539,758 | 0.00 | — | 539,758 | — | ↗ |
| 2022-08-23 | Pamukcu Rifat | Director | C-Conversion | D | Series A Non-Voting Convertible Preferred Stock | 27,187 | 0.00 | — | 0 | — | ↗ |
| 2022-08-23 | Gilad Oren | Director / Officer | C-Conversion | A | Common Stock | 6,045,100 | 0.00 | — | 6,375,414 | — | ↗ |
| 2022-08-23 | Duey Marc | Director | C-Conversion | A | Common Stock | 11,610 | 0.00 | — | 602 | — | ↗ |
| 2022-07-28 | Seizinger Bernd R. | Director | A-Award | A | Stock Option (right to Buy) | 29,575 | 1.09 | 32.2K | 29,575 | — | ↗ |
| 2022-07-28 | SCHADE CHRISTIAN S | Director | A-Award | A | Stock Option (right to Buy) | 47,600 | 1.09 | 51.9K | 47,600 | — | ↗ |
| 2022-07-28 | Peters Richard | Director | A-Award | A | Common Stock | 5,995 | 0.00 | — | 10,605 | — | ↗ |
| 2022-07-28 | Korbel Gregory Alan | Officer | A-Award | A | Common Stock | 24,300 | 0.00 | — | 45,762 | — | ↗ |
| 2022-07-28 | HENNEMAN JOHN B III | Director | A-Award | A | Common Stock | 5,995 | 0.00 | — | 15,605 | — | ↗ |
| 2022-07-28 | Grissinger Michael | Director | A-Award | A | Common Stock | 5,995 | 0.00 | — | 5,995 | — | ↗ |
| 2022-07-28 | Coiante Scott M | Officer | A-Award | A | Stock Option (right to Buy) | 89,200 | 1.09 | 97.2K | 89,200 | — | ↗ |
| 2022-06-03 | SCHADE CHRISTIAN S | Director / Officer | F-InKind | D | Common Stock | 65,770 | 0.81 | 52.9K | 226,846 | — | ↗ |
| 2022-06-03 | Korbel Gregory Alan | Director / Officer | F-InKind | D | Common Stock | 8,390 | 0.81 | 6.8K | 21,462 | — | ↗ |
| 2022-06-03 | Coiante Scott M | Director / Officer | F-InKind | D | Common Stock | 35,284 | 0.81 | 28.4K | 84,265 | — | ↗ |
| 2022-05-18 | Seizinger Bernd R. | Director | P-Purchase | A | Common Stock | 50,000 | 0.71 | 35.5K | 318,580 | — | ↗ |
| 2022-05-18 | SCHADE CHRISTIAN S | Director / Officer | P-Purchase | A | Common Stock | 37,500 | 0.64 | 24.1K | 292,616 | — | ↗ |
| 2022-05-16 | Grissinger Michael | Director | — | D | Stock Option (right to buy) | 72,638 | 0.44 | 32.0K | 0 | — | ↗ |
| 2022-03-10 | SCHADE CHRISTIAN S | Director / Officer | A-Award | A | Stock Option (right to Buy) | 427,700 | 1.82 | 778.4K | 427,700 | — | ↗ |
| 2022-03-10 | Korbel Gregory Alan | Director / Officer | F-InKind | D | Common Stock | 1,989 | 1.82 | 3.6K | 29,852 | — | ↗ |
| 2022-03-10 | Coiante Scott M | Director / Officer | A-Award | A | Common Stock | 42,900 | 0.00 | — | 119,549 | — | ↗ |
| 2022-03-10 | Abrahmsen Lars B. | Officer | A-Award | A | Common Stock | 24,700 | 0.00 | — | 43,700 | — | ↗ |
| 2022-02-25 | SCHADE CHRISTIAN S | Director / Officer | F-InKind | D | Common Stock | 21,644 | 1.74 | 37.7K | 155,016 | — | ↗ |
| 2022-02-25 | Korbel Gregory Alan | Officer | F-InKind | D | Common Stock | 1,326 | 1.74 | 2.3K | 15,841 | — | ↗ |
| 2022-02-25 | Coiante Scott M | Officer | F-InKind | D | Common Stock | 14,817 | 1.74 | 25.8K | 76,649 | — | ↗ |
| 2021-12-01 | Korbel Gregory Alan | Officer | M-Exempt | D | Stock Option (right to Buy) | 27,500 | 0.92 | 25.3K | 2,335 | — | ↗ |
| 2021-11-01 | Korbel Gregory Alan | Officer | M-Exempt | D | Stock Option (right to Buy) | 2,255 | 0.92 | 2.1K | 29,835 | — | ↗ |
| 2021-10-01 | Korbel Gregory Alan | Officer | M-Exempt | A | Common Stock | 27,500 | 0.92 | 25.3K | 44,667 | — | ↗ |
| 2021-10-01 | Abrahmsen Lars B. | Officer | M-Exempt | A | Common Stock | 50,000 | 0.92 | 46.0K | 69,000 | — | ↗ |
| 2021-09-20 | Korbel Gregory Alan | Officer | S-Sale | D | Common Stock | 27,500 | 4.97 | 136.7K | 17,167 | — | ↗ |
| 2021-09-20 | Abrahmsen Lars B. | Officer | M-Exempt | A | Common Stock | 25,000 | 0.92 | 23.0K | 44,000 | — | ↗ |
| 2021-09-10 | Korbel Gregory Alan | Officer | F-InKind | D | Common Stock | 1,724 | 4.59 | 7.9K | 22,627 | — | ↗ |
| 2021-08-25 | Korbel Gregory Alan | Officer | F-InKind | D | Common Stock | 1,149 | 3.98 | 4.6K | 24,351 | — | ↗ |
| 2021-08-25 | Coiante Scott M | Officer | F-InKind | D | Common Stock | 7,534 | 3.98 | 30.0K | 91,466 | — | ↗ |
| 2021-06-30 | Seizinger Bernd R. | Director | A-Award | A | Common Stock | 4,610 | 0.00 | — | 268,580 | — | ↗ |
| 2021-06-30 | Peters Richard | Director | A-Award | A | Stock Option (Right to Buy) | 22,750 | 4.88 | 111.0K | 22,750 | — | ↗ |
| 2021-06-30 | Namouni Fouad | Director | A-Award | A | Stock Option (Right to Buy) | 22,750 | 4.88 | 111.0K | 22,750 | — | ↗ |
| 2021-06-30 | HENNEMAN JOHN B III | Director | A-Award | A | Stock Option (Right to Buy) | 22,750 | 4.88 | 111.0K | 22,750 | — | ↗ |
| 2021-03-10 | Korbel Gregory Alan | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 25,500 | — | ↗ |
| 2021-02-25 | SCHADE CHRISTIAN S | Director / Officer | A-Award | A | Common Stock | 77,000 | 0.00 | — | 77,160 | — | ↗ |
| 2021-02-25 | Korbel Gregory Alan | Officer | A-Award | A | Stock Option (right to Buy) | 41,100 | 6.00 | 246.6K | 41,100 | — | ↗ |
| 2021-02-25 | Coiante Scott M | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 35,500 | — | ↗ |
| 2021-02-25 | Abrahmsen Lars B. | Officer | A-Award | A | Stock Option (right to Buy) | 82,000 | 6.00 | 492.0K | 82,000 | — | ↗ |
| 2020-12-28 | Redmile Group, LLC | 10% Owner | S-Sale | D | Common Stock | 494,137 | 5.58 | 2.76M | 1,774,581 | — | ↗ |
| 2020-10-05 | 5AM Ventures IV, L.P. | 10% Owner | S-Sale | D | Common Stock | 175,000 | 25.30 | 4.43M | 138,497 | — | ↗ |
| 2020-07-07 | KDev Investments AB | 10% Owner | S-Sale | D | Common Stock | 241,703 | 34.55 | 8.35M | 1,992,586 | — | ↗ |
| 2020-06-30 | Seizinger Bernd R. | Director | A-Award | A | Stock Option (right to Buy) | 5,600 | 38.78 | 217.2K | 5,600 | — | ↗ |
| 2020-06-30 | ROCKLAGE SCOTT M | Director | A-Award | A | Stock Option (right to Buy) | 5,600 | 38.78 | 217.2K | 5,600 | — | ↗ |
| 2020-06-30 | Hepple Jonathan | Director | A-Award | A | Stock Option (right to Buy) | 5,600 | 38.78 | 217.2K | 5,600 | — | ↗ |
| 2020-06-26 | Peters Richard | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-26 | Namouni Fouad | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-16 | ROCKLAGE SCOTT M | Director / 10% Owner | S-Sale | D | Common Stock | 115,357 | 33.30 | 3.84M | 1,823,192 | — | ↗ |
| 2020-06-16 | 5AM Ventures IV, L.P. | 10% Owner | S-Sale | D | Common Stock | 115,357 | 33.30 | 3.84M | 1,823,192 | — | ↗ |
| 2020-06-11 | ROCKLAGE SCOTT M | Director / 10% Owner | S-Sale | D | Common Stock | 235,200 | 28.75 | 6.76M | 1,938,549 | — | ↗ |
| 2020-06-11 | 5AM Ventures IV, L.P. | 10% Owner | S-Sale | D | Common Stock | 235,200 | 28.75 | 6.76M | 1,938,549 | — | ↗ |
| 2020-05-19 | ROCKLAGE SCOTT M | Director | S-Sale | D | Common Stock | 244,800 | 35.15 | 8.60M | 2,173,748 | — | ↗ |
| 2020-05-19 | 5AM Ventures IV, L.P. | 10% Owner | S-Sale | D | Common Stock | 10,200 | 35.15 | 358.5K | 90,572 | — | ↗ |
| 2020-05-18 | Versant Vantage I, L.P. | 10% Owner | J-Other | D | Common Stock | 116,664 | 0.00 | — | 216,669 | — | ↗ |
| 2020-05-18 | Versant V Luxco S.a r.l. | 10% Owner | J-Other | A | Common Stock | 1,178 | 0.00 | — | 1,178 | — | ↗ |
| 2020-04-13 | KDev Investments AB | 10% Owner | S-Sale | D | Common Stock | 210,548 | 31.25 | 6.58M | 2,234,289 | — | ↗ |
| 2020-04-09 | Versant V Luxco S.a r.l. | 10% Owner | J-Other | A | Common Stock | 66,506 | 0.00 | — | 66,506 | — | ↗ |
| 2020-03-24 | SCHADE CHRISTIAN S | Director / Officer | A-Award | A | Stock Option (right to Buy) | 127,000 | 35.50 | 4.51M | 127,000 | — | ↗ |
| 2020-03-24 | Korbel Gregory Alan | Officer | A-Award | A | Stock Option (right to Buy) | 12,800 | 35.50 | 454.4K | 12,800 | — | ↗ |
| 2020-03-24 | Coiante Scott M | Officer | A-Award | A | Stock Option (right to Buy) | 55,000 | 35.50 | 1.95M | 55,000 | — | ↗ |
| 2020-03-24 | Abrahmsen Lars B. | Officer | A-Award | A | Stock Option (right to Buy) | 31,600 | 35.50 | 1.12M | 31,600 | — | ↗ |
| 2019-10-07 | Versant Vantage I, L.P. | 10% Owner | C-Conversion | A | Common Stock | 512,995 | 0.00 | — | 2,519,323 | — | ↗ |
| 2019-10-07 | Versant V Luxco S.a r.l. | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 15.00 | 5.00M | 333,333 | — | ↗ |
| 2019-10-07 | Seizinger Bernd R. | Director | M-Exempt | D | Stock Option (right to buy) | 263,970 | 0.07 | 18.5K | 0 | — | ↗ |
| 2019-10-07 | SCHADE CHRISTIAN S | Director / Officer | A-Award | A | Stock Option (right to Buy) | 306,085 | 15.00 | 4.59M | 306,085 | — | ↗ |
| 2019-10-07 | Redmile Group, LLC | 10% Owner | C-Conversion | A | Common Stock | 1,868,718 | 0.00 | — | 1,868,718 | — | ↗ |
| 2019-10-07 | ROCKLAGE SCOTT M | Director | C-Conversion | D | Series C Convertible Preferred Stock | 20,519 | 0.00 | — | 0 | — | ↗ |
| 2019-10-07 | Magni Guido | Director | P-Purchase | A | Common Stock | 6,500 | 15.00 | 97.5K | 6,500 | — | ↗ |
| 2019-10-07 | Korbel Gregory Alan | Officer | A-Award | A | Stock Option (right to Buy) | 64,322 | 15.00 | 964.8K | 64,322 | — | ↗ |
| 2019-10-07 | KDev Investments AB | 10% Owner | C-Conversion | A | Common Stock | 1,600,559 | 0.00 | — | 2,444,837 | — | ↗ |
| 2019-10-07 | Coiante Scott M | Officer | P-Purchase | A | Common Stock | 2,500 | 15.00 | 37.5K | 2,500 | — | ↗ |
| 2019-10-07 | Abrahmsen Lars B. | Officer | A-Award | A | Stock Option (right to Buy) | 77,630 | 15.00 | 1.16M | 77,630 | — | ↗ |
| 2019-10-07 | 5AM Ventures IV, L.P. | 10% Owner | C-Conversion | A | Common Stock | 492,475 | 0.00 | — | 2,418,548 | — | ↗ |
| 2019-10-02 | Versant V Luxco S.a r.l. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 12,670 | — | ↗ |
| 2019-10-02 | Seizinger Bernd R. | Director | — | D | Stock Option (right to buy) | 263,970 | 0.07 | 18.5K | 0 | — | ↗ |
| 2019-10-02 | SCHADE CHRISTIAN S | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 160 | — | ↗ |
| 2019-10-02 | Redmile Group, LLC | 10% Owner | — | I | Series C Preferred Stock | 1,868,718 | 0.00 | — | 0 | — | ↗ |
| 2019-10-02 | ROCKLAGE SCOTT M | Director | — | I | Series C Convertible Preferred Stock | 20,519 | 0.00 | — | 0 | — | ↗ |
| 2019-10-02 | Magni Guido | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-10-02 | Korbel Gregory Alan | Officer | — | D | Stock Option (right to buy) | 82,631 | 3.19 | 263.6K | 0 | — | ↗ |
| 2019-10-02 | KDev Investments AB | 10% Owner | — | I | Series A Convertible Preferred Stock | 579,647 | 0.00 | — | 0 | — | ↗ |
| 2019-10-02 | Hepple Jonathan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-10-02 | Coiante Scott M | Officer | — | D | Stock Option (right to buy) | 186,539 | 10.95 | 2.04M | 0 | — | ↗ |
| 2019-10-02 | Abrahmsen Lars B. | Officer | — | D | Stock Option (right to buy) | 101,083 | 3.19 | 322.5K | 0 | — | ↗ |
| 2019-10-02 | 5AM Ventures IV, L.P. | 10% Owner | — | I | Series C Convertible Preferred Stock | 20,519 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.49M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Oren Gilad, Ph.D. President and Chief Executive Officer | 594.9K | — | 14.8K | 43.6K | — | 4.0K | 657.3K | 8.88% | ↗ |
| 2 | 2025 | John P. Hamill Chief Financial Officer | 454.3K | — | 7.4K | 21.8K | — | 7.2K | 490.7K | 5.95% | ↗ |
| 3 | 2024 | Oren Gilad, Ph.D. President and Chief Executive Officer | 572.0K | — | 45.0K | 139.6K | — | 3.5K | 760.1K | 24.29% | ↗ |
| 4 | 2024 | John P. Hamill Chief Financial Officer | 437.1K | — | 22.5K | 69.9K | — | 7.2K | 536.6K | 17.21% | ↗ |
| 5 | 2024 | Nadeem Q. Mirza, M.D., M.P.H. Former Chief Medical Officer | 281.4K | — | 35.3K | 105.3K | — | 25.7K | 447.7K | 31.40% | ↗ |
| 6 | 2023 | John P. Hamill Chief Financial Officer | 387.9K | — | 133.9K | 197.3K | 189.3K | — | 908.4K | 36.45% | ↗ |
| 7 | 2023 | Oren Gilad, Ph.D. President and Chief Executive Officer | 550.0K | — | 20.3K | 60.2K | 247.0K | — | 877.4K | 9.17% | ↗ |
| 8 | 2023 | Scott M. Coiante Former Chief Financial Officer | 100.0K | — | — | — | — | 300.0K | 400.0K | 0.00% | ↗ |
| 9 | 2022 | Christian S. Schade Chairman and Chief Executive Officer (through July 28, 2022) | 328.4K | — | 182.2K | 581.7K | 281.5K | — | 1.37M | 55.60% | ↗ |
| 10 | 2022 | Scott M. Coiante Former Chief Financial Officer | 400.0K | — | 144.4K | 326.0K | 160.0K | — | 1.03M | 45.65% | ↗ |
| 11 | 2022 | Eyal C. Attar, M.D. Chief Medical Officer (through August 15, 2022) | 329.0K | — | 78.1K | 252.8K | 115.5K | — | 775.4K | 42.68% | ↗ |
| 12 | 2022 | Oren Gilad, Ph.D. President and Chief Executive Officer | 323.6K | — | 110.4K | 121.9K | 197.3K | — | 753.2K | 30.85% | ↗ |
| 13 | 2022 | Gregory A. Korbel, Ph.D. Former Chief Operating Officer | 310.4K | — | 55.6K | 128.0K | 107.3K | — | 601.3K | 30.54% | ↗ |
| 14 | 2021 | Christian S. Schade Chairman and Chief Executive Officer | 530.5K | — | 993.0K | 1.44M | 265.2K | — | 3.23M | 75.39% | ↗ |
| 15 | 2021 | Christian S. Schade Chairman and Chief Executive Officer (through July 28, 2022) | 530.5K | — | 993.0K | 1.44M | 265.2K | — | 3.23M | 75.39% | ↗ |
| 16 | 2021 | Eyal C. Attar, M.D. Chief Medical Officer (through August 15, 2022) | 450.9K | — | 648.0K | 627.8K | 180.0K | — | 1.91M | 66.91% | ↗ |
| 17 | 2021 | Eyal C. Attar Chief Medical Officer | 450.9K | — | 648.0K | 627.8K | 180.0K | — | 1.91M | 66.91% | ↗ |
| 18 | 2021 | Scott M. Coiante Chief Financial Officer | 381.1K | — | 579.0K | 627.8K | 155.0K | — | 1.74M | 69.24% | ↗ |
| 19 | 2021 | Scott M. Coiante Former Chief Financial Officer | 381.1K | — | 579.0K | 627.8K | 155.0K | — | 1.74M | 69.24% | ↗ |
| 20 | 2021 | Gregory A. Korbel, Ph.D. Former Chief Operating Officer | 271.9K | — | 146.0K | 180.4K | 69.0K | — | 667.2K | 48.91% | ↗ |
| 21 | 2020 | Christian S. Schade Chairman and Chief Executive Officer | 515.0K | — | — | 3.11M | 283.3K | — | 3.91M | 79.56% | ↗ |
| 22 | 2020 | Christian S. Schade President and Chief Executive Officer | 515.0K | — | — | 3.11M | 283.3K | — | 3.91M | 79.56% | ↗ |
| 23 | 2020 | Eyal C. Attar Chief Medical Officer | 437.8K | — | — | 1.35M | 192.6K | — | 1.98M | 68.10% | ↗ |
| 24 | 2020 | Scott M. Coiante Chief Financial Officer | 370.0K | — | — | 1.35M | 142.5K | — | 1.86M | 72.42% | ↗ |
| 25 | 2019 | Christian S. Schade President and Chief Executive Officer | 446.4K | — | — | 3.02M | 210.1K | — | 3.68M | 82.15% | ↗ |
| 26 | 2019 | Scott M. Coiante Chief Financial Officer | 143.2K | 50.0K | — | 1.49M | 127.6K | — | 1.81M | 82.27% | ↗ |
| 27 | 2019 | Eyal C. Attar Chief Medical Officer | 301.3K | — | — | 766.2K | 121.8K | — | 1.19M | 64.43% | ↗ |
| 28 | 2018 | Christian S. Schade President and Chief Executive Officer | 412.0K | 181.3K | — | — | — | — | 593.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Oren Gilad | Co-Founder, Chief Executive Officer, President and Director | 598.9K | — |
| John Hamill | Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary | 461.4K | male |
| Eugene Kennedy | Chief Medical Advisor | — | — |
| Lars Abrahmsen | Senior Vice President & Chief Scientific Officer | — | — |
| Michel Afargan | Head of Pharmacology Development | — | — |
| Andrea Epstein | Controller | — | female |
| Zeev Weiss | Chief Business Advisor | — | male |
| Brian Wiley | Senior Vice President of Corporate Development & Strategy | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APRE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
